Cardiovascular Risk in Diabetes: Evidence and Outcomes

Evidence on improving cardiovascular risk

Evidence related to cardiovascular risk, cardiovascular events, ASCVD risk, vascular function, functional capacity, and mortality outcomes in diabetes studies.

Build your Evidence Workspace

Save evidence about the topics you care about.

Studies

Evidence Pairs

Moderate Research

Evidence Base: 66/100

Evidence Intelligence™

Evidence Summary

A structured summary of where the evidence is strongest, mixed, or still emerging.

Executive Summary

Cardiovascular Risk evidence appears to center on Semaglutide.

Among 44 indexed studies and 38 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.

Evidence is consistently positive across multiple studies.
Some evidence is positive, but results are not consistent across all studies.
Early findings are encouraging, but stronger trials are needed.

Caution

This summary reflects the currently indexed evidence and should not be interpreted as treatment advice.

Key Finding

Evidence is consistently positive across multiple studies.

Interventions with strongest consistent evidence

Strongest consistent evidence

Why it matters

Consistent positive findings are easier to interpret than isolated or mixed results.

Interpretation

Semaglutide appears to have a consistent beneficial signal in the indexed evidence.

View supporting studies

Evidence basis: 13 evidence pairs - 13 studies

Why this appears here

Strong evidenceGenerally consistentPositive effect signalMultiple RCTsModerate evidenceConsistent results

Semaglutide

10 studies

EvidenceScore™

83/100

ConsistencyScore™

38/100

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

3 studies

EvidenceScore™

69/100

ConsistencyScore™

100/100

Evidence Snapshot

Studies

Interventions

Outcomes

Strong evidence signals

Mixed evidence areas

Key Findings

Key patterns and insights identified across the research landscape

Strong positive signal

Semaglutide shows strong evidence for improving Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Semaglutide → Composite cardiovascular events (CV death, MI, stroke, HF hospitalization)

Across 7 studies, Semaglutide shows a strong positive signal for Composite cardiovascular events (CV death, MI, stroke, HF hospitalization).

7 studies

EvidenceScore™: 83.20879120879121/100

View supporting studies

Evidence signal

Semaglutide shows evidence for All-cause mortality

Semaglutide → All-cause mortality

Across 6 studies, Semaglutide shows a evidence signal for All-cause mortality.

6 studies

EvidenceScore™: 82.94871794871796/100

View supporting studies

Evidence signal

Semaglutide shows evidence for Nonfatal stroke

Semaglutide → Nonfatal stroke

Across 4 studies, Semaglutide shows a evidence signal for Nonfatal stroke.

4 studies

EvidenceScore™: 79/100

View supporting studies

Strong positive signal

Semaglutide shows strong evidence for improving Cardiovascular events

Semaglutide → Cardiovascular events

Across 3 studies, Semaglutide shows a consistent strong positive signal for Cardiovascular events.

3 studies

EvidenceScore™: 79/100

View supporting studies

Evidence signal

Semaglutide shows evidence for Cardiovascular death

Semaglutide → Cardiovascular death

Across 3 studies, Semaglutide shows a evidence signal for Cardiovascular death.

3 studies

EvidenceScore™: 77.07692307692308/100

View supporting studies

Supporting Evidence

Mixed or conflicting evidence

Some evidence is positive, but results are not consistent across all studies.

Areas where results are mixed

Why it matters

Mixed results suggest effects may depend on population, comparator, duration, or study design.

Interpretation

Semaglutide is mixed in the currently indexed evidence.

Caution

Some supporting studies reported neutral, negative, or mixed findings.

Top entities

Semaglutide

Intensive glycemic control

Semaglutide

10 studies

EvidenceScore™

83/100

ConsistencyScore™

38/100

Why this appears here

Mixed Or Conflicting ResultsPositive Signal PresentNeutral Results PresentNegative Results Present

Evidence basis: 21 evidence pairs - 16 studies

View supporting studies

Promising but understudied

Early findings are encouraging, but stronger trials are needed.

Promising areas needing more evidence

Why it matters

Promising signals can guide further review, but they should not be treated as settled evidence.

Interpretation

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) may have a beneficial signal, but the evidence base is still developing.

Caution

Current support is limited by study volume, RCT depth, or evidence strength.

Top entities

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

SGLT2 inhibitors

Finerenone (nonsteroidal mineralocorticoid receptor antagonist)

3 studies

EvidenceScore™

69/100

ConsistencyScore™

100/100

Why this appears here

Positive effect signalLimited study volumeFew randomized trialsEmerging Or Limited Strength

Evidence basis: 15 evidence pairs - 8 studies

View supporting studies

Question Highlights

Quick answers to the most important questions supported by the available evidence.

Explore all evidence questions

What improves cardiovascular risk?

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular Risk.

Semaglutide, Finerenone (nonsteroidal mineralocorticoid receptor antagonist), and SGLT2 inhibitors are among the best-supported options in the available evidence across 44 studies.

Consistency cannot yet be determined.

View full answer

Does Semaglutide improve cardiovascular risk?

Semaglutide appears to improve Cardiovascular events.

Strong evidence is based on 10 supporting studies.

The evidence includes both beneficial and harmful or worsening results.

View full answer

How can I lower cardiovascular events?

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular events.

Emerging evidence is based on 6 supporting studies.

Consistency cannot yet be determined.

View full answer

Explore all evidence questions

Explore the Evidence

The sections below provide the complete evidence questions, supporting relationships, and underlying studies behind the summary above.

Questions Answered by the Evidence

What improves cardiovascular risk?

outcome achievement

Emerging Evidence

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular Risk.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies
2
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 3 studies
3
SGLT2 inhibitors
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is based on 44 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

Does Semaglutide improve cardiovascular risk?

intervention effectiveness

Strong Evidence

Semaglutide appears to improve Cardiovascular events.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Population details are unavailable.

Does Intensive glycemic control improve cardiovascular risk?

intervention effectiveness

Moderate Evidence

Current evidence does not show a clear benefit of Intensive glycemic control for Cardiovascular events.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: Some evidence reported benefits while other evidence found little or no effect.

Ranked evidence signals

1
Intensive glycemic control
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Only a small number of supporting studies are available.
Population details are unavailable.

Does Finerenone (nonsteroidal mineralocorticoid receptor antagonist) improve cardiovascular risk?

intervention effectiveness

Emerging Evidence

Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to improve Cardiovascular events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 3 studies

Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

Semaglutide vs Intensive glycemic control for cardiovascular risk?

compare

Strong Evidence

Semaglutide and Intensive glycemic control have available evidence for Cardiovascular Risk, but the comparison requires review of the underlying studies.

ConsistencyScore™: Results are mixed and should be interpreted cautiously.

Evidence caveat: The evidence includes both beneficial and harmful or worsening results.

Ranked evidence signals

1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies
2
Intensive glycemic control
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | neutral | ConsistencyScore™ Mixed | 2 studies

Why this answer: This answer is cautious because the available studies report mixed findings.

Limitations

Population details are unavailable.

How can I lower cardiovascular events?

sub outcome

Emerging Evidence

Semaglutide, Intensive glycemic control, and Finerenone (nonsteroidal mineralocorticoid receptor antagonist) are among the most studied approaches for Cardiovascular events.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 79.0 | strong positive | ConsistencyScore™ Consistent | 3 studies
2
Insulin therapy
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
3
Multifactorial Therapy (MT)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on 6 supporting studies and existing graph evidence signals.

Limitations

Consistency cannot yet be determined.
Population details are unavailable.

What has the strongest evidence for cardiovascular risk?

evidence strength

Strong Evidence

Semaglutide have the strongest available evidence signals in this evidence set.

ConsistencyScore™: Results are generally consistent across studies.

Ranked evidence signals

1
Semaglutide
EvidenceScore™ Strong | EvidenceScore™ 83.2 | strong positive | ConsistencyScore™ Generally Consistent | 10 studies

Why this answer: This answer is based on 10 supporting studies with generally consistent results and a positive effect signal.

Limitations

Population details are unavailable.

Which interventions need more research for cardiovascular risk?

research gaps

Limited Evidence

More research is needed before firm conclusions can be drawn.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

1
Vegetables-first eating pattern
EvidenceScore™ Limited | EvidenceScore™ 31.8 | neutral | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

Only one supporting study is available.
Consistency cannot yet be determined.
Population details are unavailable.

Evidence summary for AI and search

Among 44 indexed studies and 38 interventions, the strongest signals are summarized from the available evidence. Semaglutide appears to be one of the clearer current evidence signals.